In the phase 1 clinical trial (NCT03260491), patritumab deruxtecan demonstrated significant clinical efficacy, which it granted breakthrough therapy designation by the FDA for the treatment of patients with metastatic or locally advanced, EGFR-mutated NSCLC. Here, EGFR is linked to non-small cell lung carcinoma.